<DOC>
	<DOCNO>NCT00003636</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining surgery chemotherapy may kill tumor cell . It yet know whether chemotherapy surgery effective chemotherapy surgery treat ovarian , peritoneal , fallopian tube cancer . PURPOSE : This randomized phase III trial study chemotherapy give surgery see well work compare chemotherapy give surgery without additional surgery treat patient stage III stage IV ovarian cancer , peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Surgery Treating Patients With Stage III Stage IV Ovarian , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival progression-free survival patient stage IIIC IV ovarian epithelial , peritoneal , fallopian tube carcinoma treat neoadjuvant chemotherapy follow interval debulking surgery versus upfront cytoreductive surgery follow chemotherapy without interval debulking surgery . - Compare quality life patient treat regimen . - Compare different treatment complication patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , method biopsy , stage , large tumor size surgery , intent also randomize EORTC-55012 . Patients randomize one two treatment arm . - Arm I : Patients undergo upfront maximal cytoreductive surgery follow cisplatin carboplatin IV every 3 week 3 course . Patients non-optimal primary debulking may undergo interval debulking surgery physician 's discretion . All patient receive additional 3 course regimen chemotherapy . - Arm II : Patients receive chemotherapy arm I . Patients stable respond disease undergo interval debulking surgery follow additional 3 course regimen chemotherapy . Second-look surgery allow arm clinically indicate . Quality life ( QOL ) assess prior treatment , third sixth course chemotherapy , 6 12 month study . Patients also randomize EORTC-55012 follow QOL assessment schedule EORTC-55012 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 704 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIC IV ovarian epithelial carcinoma , peritoneal carcinoma , fallopian tube carcinoma If biopsy available , evidence adenocarcinoma fine needle aspiration allow follow true : Presence pelvic ovarian mass Omental cake metastasis large 2 cm upper abdomen and/or regional lymph node metastasis CA 125/carcinoembryonic antigen ratio great 25 ( ratio less 25 , barium enema colonoscopy AND gastroscopy radiological examination stomach must negative primary tumor ) Normal mammography ( CA 125/carcinoembryonic antigen ratio le 25 ) Tumor great 2 cm , exclude ovary , laparoscopy CT scan No brain leptomeningeal metastases PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.25 time upper limit normal ( ULN ) Renal : Creatinine le 1.25 time ULN Other : No serious disabling disease contraindicate primary cytoreductive surgery primary platinbased chemotherapy No prior primary malignancy except carcinoma situ cervix basal cell carcinoma skin No psychological , familial , sociological , geographical condition potentially prevent protocol compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery No prior procedures except diagnostic biopsy laparotomy laparoscopy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>